Mahsa Khayat-Khoei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mahsa Khayat-Khoei has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Habibollah Peirovi
Nanomedicine and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications- Hassan Niknejad
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications Alessio Boschi
Department of Neurology, Brigham & Women’s Hospital
1 shared publication- Alexander W. E. Dunn
Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
1 shared publication - András Lakatos
John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
1 shared publication - Anusha Gandhi
Baylor college of Medicine, Houston, USA
1 shared publication
Latest Publications
- Open Access
MEA-NAP compares microscale functional connectivity, topology, and network dynamics in organoid or monolayer neuronal cultures
Summary: Microelectrode array (MEA) recordings are commonly used to compare firing and burst rates in neuronal cultures. MEA recordings can also reveal microscale functional connectivity, topology, and network dynamics—patterns seen in brain networks across spatial scales. Network topology is frequently characterized in neuroimaging with graph theoretical metrics. However, few computational tools exist for analyzing microscale functional brain networks from MEA recordings. Here, we present a MATLAB MEA network analysis pipeline (MEA-NAP) for raw voltage time-series acquired from single- or multi-well MEAs. Applications to 3D human cerebral organoids or 2D human-derived or murine cultures reveal differences in network development, including topology, node cartography, and dimensionality. MEA-NAP incorporates multi-unit template-based spike detection, probabilistic thresholding for determining significant functional connections, and normalization techniques for comparing networks. MEA-NAP can identify network-level effects of pharmacologic perturbation and/or disease-causing mutations and, thus, can provide a translational platform for revealing mechanistic insights and screening new therapeutic approaches.
Open AccessMEA-NAP compares microscale functional connectivity, topology, and network dynamics in organoid or monolayer neuronal cultures
Summary: Microelectrode array (MEA) recordings are commonly used to compare firing and burst rates in neuronal cultures. MEA recordings can also reveal microscale functional connectivity, topology, and network dynamics—patterns seen in brain networks across spatial scales. Network topology is frequently characterized in neuroimaging with graph theoretical metrics. However, few computational tools exist for analyzing microscale functional brain networks from MEA recordings. Here, we present a MATLAB MEA network analysis pipeline (MEA-NAP) for raw voltage time-series acquired from single- or multi-well MEAs. Applications to 3D human cerebral organoids or 2D human-derived or murine cultures reveal differences in network development, including topology, node cartography, and dimensionality. MEA-NAP incorporates multi-unit template-based spike detection, probabilistic thresholding for determining significant functional connections, and normalization techniques for comparing networks. MEA-NAP can identify network-level effects of pharmacologic perturbation and/or disease-causing mutations and, thus, can provide a translational platform for revealing mechanistic insights and screening new therapeutic approaches.
- 4 September 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1093-1106
COVID-19 mRNA vaccination leading to CNS inflammation: a case series
The availability of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID-19) pandemic. Vaccine safety and efficacy has not been established in individuals with chronic autoimmune diseases such as multiple sclerosis (MS). Anecdotal reports suggest that the vaccines may be associated with brain, spinal cord, peripheral nervous system, and cardiac inflammation. Based on the high morbidity and unpredictable course of COVID-19, and the need to achieve herd immunity, vaccination has been recommended for patients with MS. We report clinical and MRI features of seven individuals who received the Moderna (n = 3) or Pfizer (n = 4) SARS-CoV-2 mRNA vaccines. Within one to 21 days of either the first (n = 2) or second (n = 5) vaccine dose, these patients developed neurologic symptoms and MRI findings consistent with active CNS demyelination of the optic nerve, brain, and/or spinal cord. Symptoms included visual loss, dysmetria, gait instability, paresthesias, sphincter disturbance, and limb weakness. Age ranged from 24 to 64 (mean 39.1) years; five were woman (71.4%). The final diagnosis was exacerbation of known stable MS (n = 4, two were receiving disease-modifying therapy at the time of vaccination), new onset MS (n = 2), or new onset neuromyelitis optica (n = 1). All responded to corticosteroid (n = 7) or plasma exchange (n = 1) therapy, with five returning to baseline and two approaching baseline. Large prospective studies are required to further investigate any possible relationship between COVID-19 vaccines and acute CNS demyelination.
- 4 September 2021
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1093-1106
COVID-19 mRNA vaccination leading to CNS inflammation: a case series
The availability of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID-19) pandemic. Vaccine safety and efficacy has not been established in individuals with chronic autoimmune diseases such as multiple sclerosis (MS). Anecdotal reports suggest that the vaccines may be associated with brain, spinal cord, peripheral nervous system, and cardiac inflammation. Based on the high morbidity and unpredictable course of COVID-19, and the need to achieve herd immunity, vaccination has been recommended for patients with MS. We report clinical and MRI features of seven individuals who received the Moderna (n = 3) or Pfizer (n = 4) SARS-CoV-2 mRNA vaccines. Within one to 21 days of either the first (n = 2) or second (n = 5) vaccine dose, these patients developed neurologic symptoms and MRI findings consistent with active CNS demyelination of the optic nerve, brain, and/or spinal cord. Symptoms included visual loss, dysmetria, gait instability, paresthesias, sphincter disturbance, and limb weakness. Age ranged from 24 to 64 (mean 39.1) years; five were woman (71.4%). The final diagnosis was exacerbation of known stable MS (n = 4, two were receiving disease-modifying therapy at the time of vaccination), new onset MS (n = 2), or new onset neuromyelitis optica (n = 1). All responded to corticosteroid (n = 7) or plasma exchange (n = 1) therapy, with five returning to baseline and two approaching baseline. Large prospective studies are required to further investigate any possible relationship between COVID-19 vaccines and acute CNS demyelination.
- Open Access
- 12 February 2021
- Published by Springer Nature in Research Square
Negative Anti-SARS-CoV-2 S Antibody Response Following Pfizer SARS-CoV-2 Vaccination in a Patient on Ocrelizumab
Several vaccines for novel Coronavirus (SARS-CoV-2) are now available. In Multiple Sclerosis (MS) patients on anti-CD20 therapy, blunted antibody responses to SARS-CoV-2 infection and to some vaccines have been reported. However, there is no data on immune response to mRNA vaccines against SARS-CoV-2 in patients on anti-CD20 therapies. We present a patient with MS on ocrelizumab, who received the Pfizer mRNA COVID-19 vaccine, and did not seroconvert 27 days after the second vaccine dose as measured by an FDA approved Anti-SARS-CoV-2 S assay.
- 12 February 2021
- Published by Springer Nature in Research Square
Open AccessNegative Anti-SARS-CoV-2 S Antibody Response Following Pfizer SARS-CoV-2 Vaccination in a Patient on Ocrelizumab
Several vaccines for novel Coronavirus (SARS-CoV-2) are now available. In Multiple Sclerosis (MS) patients on anti-CD20 therapy, blunted antibody responses to SARS-CoV-2 infection and to some vaccines have been reported. However, there is no data on immune response to mRNA vaccines against SARS-CoV-2 in patients on anti-CD20 therapies. We present a patient with MS on ocrelizumab, who received the Pfizer mRNA COVID-19 vaccine, and did not seroconvert 27 days after the second vaccine dose as measured by an FDA approved Anti-SARS-CoV-2 S assay.
- 1 January 2014
- Published by Elsevier in Cytotherapy
- Vol. 16 (1) , 33-40
Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy
- 1 January 2014
- Published by Elsevier in Cytotherapy
- Vol. 16 (1) , 33-40
Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy
- 1 May 2012
- Published by Elsevier in Medical Hypotheses
- Vol. 78 (5) , 690-691
Inhibition of MMPs might increase anticancer properties of amniotic epithelial cells
- 1 May 2012
- Published by Elsevier in Medical Hypotheses
- Vol. 78 (5) , 690-691
Inhibition of MMPs might increase anticancer properties of amniotic epithelial cells